MedTrace Logo

To Demonstrate the Relative Bioequivalence of Cefdinir and Omnicef 300 mg Capsule Fasting Conditions

NCT00882700 · Status: COMPLETED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 28

Last updated 2017-03-29

No results posted yet for this study

Summary

To demonstrate the relative bioequivalence of Cefdinir and Omnicel 300 mg capsule fasting conditions.

Conditions

  • Healthy

Interventions

DRUG

Cefdinir 300 mg Capsule (Sandoz, Austria)

DRUG

Omnicef Cefdinir 300 mg Capsule (Abbott Laboratories, USA)

Sponsors & Collaborators

Principal Investigators

  • Richard Larouche, M.D. · SFBC Anapharm

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
CROSSOVER

Eligibility

Min Age
18 Years
Max Age
56 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2005-04-30
Primary Completion
2005-04-30
Completion
2005-04-30

More Related Trials

Entities

Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00882700 on ClinicalTrials.gov